Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan + zanzalintinib versus belzutifan + placebo in advanced clear cell renal cell carcinoma
NL-OMON61145Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- May 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of belzutifan, zanzalintinib in renal cell carcinoma (RCC), sponsored by Merck & Co.. Started May 2026; status: recruiting.
02
Drugs
belzutifanzanzalintinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON61145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61145.